ArticleApplied microbiology and biotechnology2021
Relative humidity impacts development and activity against Aedes aegypti adults by granular formulations of Metarhizium humberi microsclerotia.
Article in Applied microbiology and biotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 33 citations in OpenAlex.
- Development of Mycoinsecticides: Advances in Formulation, Regulatory Challenges and Market Trends for Entomopathogenic Fungi.Journal of fungi (Basel, Switzerland) · 2025Review
- Composite function and Biomod2 for evaluating the influence of climate change on the distribution ofOne health (Amsterdam, Netherlands) · 2025Article
- Harnessing environmental microbiological interventions with micro- and macroorganisms for assessing cattle tick management.Scientific reports · 2025Article
- Future geographical distribution of Aedes albopictus in China under climate change scenarios.PloS one · 2025Article
- Microsclerotia formation of the biocontrol fungusFrontiers in microbiology · 2025Article
- Encapsulation of Beauveria bassiana conidia as a new strategy for the biological control of Aedes aegypti larvae.Scientific reports · 2024Article
- Advances in submerged liquid fermentation and formulation of entomopathogenic fungi.Applied microbiology and biotechnology · 2024Review
- Beauveria bassiana interacts with gut and hemocytes to manipulate Aedes aegypti immunity.Parasites & vectors · 2023Article
- Utilization ofFrontiers in fungal biology · 2023Review
- Increased Attraction and Stability ofJournal of fungi (Basel, Switzerland) · 2022Article
- Production of Microsclerotia byJournal of fungi (Basel, Switzerland) · 2022Article
- Article
- Efficacy of focal applications of a mycoinsecticide to control Aedes aegypti in Central Brazil.Applied microbiology and biotechnology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 2 countries.
Funding
Abstract
The impact of ambient relative humidity (RH) on conidial production of Metarhizium humberi IP 46 microsclerotia (MS) formulated in pellets or granules was investigated, and a promising granular formulation was tested against Aedes aegypti adults to confirm its efficacy. Microcrystalline cellulose (MC) and diatomaceous earth (DE) or a combination of vermiculite (VE), DE and silicon dioxide (SD) were tested as carriers in granular formulations containing MS. A range of 93-96.5% RH was critical for fungal development, and at least 96.5-98.5% RH was required for high conidial production on pellets or granules. Conidial production was clearly higher on pellets and granules prepared with VE than MC as the main carrier. VE granules containing MS were highly active against A. aegypti adults. Most mosquitoes were killed within 6 days after treatment regardless of the exposure time of adults to the formulation (1 min-24 h) or ambient humidity (75 or >98%). Production of conidia on dead adults varied between 7.3 × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.